Clinical data | |
---|---|
Other names | (8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H52N6O2 |
Molar mass | 624.874 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.[1]
Other nervous system drugs (N07X)
| |
---|---|
Stroke |
|
ALS |
|
Other |
|
|
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |